Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 22, 1994
Issued Date -
N/A
app pub date -
Sep 2, 1993
filing date -
Jun 17, 1991
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This invention discloses a method for treating human patients suffering from dermatitis, particularly severe dermatitis which does not respond adequately to non-prescription drugs. Such patients are treated using dextromethorphan (DM), an antitussive agent normally used in cough syrup. If the patient is a so-called 'extensive metabolizer,' an antioxidant drug (such as quinidine) can be coadministered to inhibit the DM-degrading activity of debrisoquin hydroxylase, an enzyme that will rapidly convert DM into its metabolite, dextrorphan. This treatment has been shown to be highly effective in treating severe dermatitis, and in most patients this drug combination causes no significant adverse side effects.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully